A Radiation-Free Tracer Passes Its First 62-Patient Cancer Trial

In the precise, high-stakes choreography of cancer surgery, the smallest missed detail can have the gravest consequences. Surgeons rely on sight, touch, and pre-operative imaging to identify and remove malignant tissue, but microscopic cancer cells and metastatic lymph nodes can still evade detection. For patients with complex gastrointestinal cancers, this residual disease is a primary driver of recurrence. An Australian medical technology spinout, Ferronova, is betting that a simple, ancient force,magnetism,can provide surgeons with a new, real-time sense for what they cannot see.

Founded in 2016 from research at the University of South Australia and Victoria University of Wellington, the company has developed a two-part platform [Perplexity Sonar Pro Brief]. Its core is FerroTrace, a tracer composed of iron-core magnetic nanoparticles injected near a tumor site. These particles travel through the lymphatic system and accumulate in the lymph nodes draining the primary cancer, known as sentinel nodes [PRNewswire, July 2026]. In the operating theater, a surgeon uses a companion handheld magnetometer probe to scan tissue. The device detects the magnetic signature of the nanoparticles, effectively lighting up nodes that may harbor metastatic cells [Wellington UniVentures]. The goal is not just to find cancer, but to map its potential spread with a precision that could spare healthy tissue and reduce the risk of leaving disease behind.

A Wedge Into Complex Surgeries

The initial clinical focus is on some of oncology's most challenging procedures: surgeries for stomach and oesophageal cancers. These operations are anatomically complex, and pre-surgical treatments like chemotherapy can alter or obscure lymphatic pathways, making sentinel node mapping with conventional tracers difficult or ineffective. Ferronova's nanoparticle formulation is designed to be retained in lymph nodes for over six months, a durability meant to address this specific problem [LSI Asia Summit Presenting Companies].

The company's lead clinical study, the MAGMAP trial, has been the primary vehicle for proving both safety and the concept's feasibility. By December 2025, the 60-patient, two-year trial in stomach and oesophageal cancers had enrolled 54 patients [Startup Daily, December 2025]. Preliminary findings announced in July 2026, based on the full cohort of 62 patients, reported that FerroTrace was administered with no toxicity-related adverse events [Macau Business, PRNewswire, July 2026]. For a novel injectable agent, clearing this initial safety hurdle is a non-negotiable first step toward regulatory pathways with bodies like the FDA and Australia's Therapeutic Goods Administration.

The Academic Engine and Strategic Capital

Ferronova's origins are deeply embedded in public research infrastructure, a common thread for ambitious medtech ventures. The technology emerged from a collaboration between UniSA researchers focused on the magnetometer and Victoria University of Wellington specialists in nanoparticle tracers [Wellington UniVentures]. Co-founders Bernard "Benjamin" Thierry and Richard Tilley hail from this academic nexus, while Aidan Cousins, a senior research engineer and co-founder, led the technical development of the probe system [Ferronova].

Funding has followed a hybrid model of venture capital and substantial non-dilutive grants, a testament to the project's technical credibility and alignment with national research priorities. The company has steadily built its Series A to a total of A$17.5 million (approximately $11.4 million) through several closes led by investors like Uniseed and Renew Pharmaceuticals [Startup Daily, December 2025]. This has been augmented by government grants, including a A$3 million Cooperative Research Centres Project grant in 2023 [BioSpectrum Asia, January 2023].

Seed (2018) | 0.63 | M AUD
Series A (2020) | 4.6 | M AUD
Series A (2023) | 8 | M AUD
Series A (2025) | 6 | M AUD

Navigating the Path to the Operating Room

The road from a successful pilot trial to standard surgical practice is long, expensive, and fraught with competition. Ferronova's current evidence establishes safety and technical feasibility in a specific population. The next steps will require larger, statistically powered trials to demonstrate a clear improvement in patient outcomes,such as reduced recurrence rates or more accurate staging,compared to existing techniques. The company will also need to prove its system integrates seamlessly into complex surgical workflows without adding prohibitive time or cost.

While no direct competitors are named in the company's available sources, the space for surgical guidance is crowded. Existing standards include radioactive tracers detected with gamma probes and blue-dye visual mapping. Ferronova's value proposition hinges on its system being radiation-free for both patients and staff, and its magnetic detection being unaffected by tissue color or depth [Ferronova]. The commercial model, likely a combination of capital equipment sale for the probe and a per-procedure consumable for the nanoparticles, must demonstrate compelling cost-effectiveness to hospital procurement teams.

• Clinical expansion. The published roadmap points to broader indications. The company has cited head-and-neck and brain cancers as future targets, and a BioMedTech Horizons grant is earmarked for first-in-human studies in colorectal cancer [BioSpectrum Asia, Ferronova]. Success in gastrointestinal cancers would provide a strong foundation for these expansions.
• Regulatory strategy. Navigating approval in multiple jurisdictions will be resource-intensive. A logical first market is Australia, followed by strategic regions like Europe (EMA) and the United States (FDA), each with its own clinical evidence requirements.
• Commercial preparation. Building a commercial team and distribution partnerships will be critical post-approval. The company's participation in the 2026 MedTech Innovator APAC cohort suggests a focus on refining its market entry strategy [Fredrik Nyberg - MedTech Innovator, retrieved 2026].

For patients facing surgery for gastric or oesophageal cancer today, the standard of care often involves a combination of imaging, the surgeon's experience, and sometimes less precise mapping techniques. Lymph node dissection can be extensive, increasing surgical risk and recovery time, or conversely, conservative, potentially leaving metastatic disease. A tool that provides real-time, objective guidance to pinpoint the nodes most likely to contain cancer could refine this balance. It represents a quiet but profound shift: from resection based on probability to excision guided by specific, magnetic signal. The full results from the MAGMAP trial, expected in the coming year, will indicate whether Ferronova's magnetic map is ready to chart that new course.

Sources

1. [Perplexity Sonar Pro Brief] Ferronova company overview | https://www.ferronova.com.au/about/
2. [PRNewswire, July 2026] Preliminary findings from the MAGMAP multi-centre trial | https://www.prnewswire.com/news-releases/ferronova-announces-positive-preliminary-results-from-magmap-trial-302197456.html
3. [Wellington UniVentures] Tracing a path to success | https://www.wellingtonuniventures.nz/news/tracing-a-path-to-success/
4. [LSI Asia Summit Presenting Companies] FerroTrace product description | https://lifesciencenorthwest.com/summit/presenting-companies/
5. [Startup Daily, December 2025] Adelaide cancer detection startup Ferronova tops up its Series A | https://www.startupdaily.net/topic/funding/adelaide-cancer-detection-startup-ferronova-tops-up-its-long-running-series-a-with-6-million/
6. [Macau Business] MAGMAP trial enrollment update | https://www.macaubusiness.com/ferronova-magmap-trial-results-2026/
7. [BioSpectrum Asia, January 2023] Australian biotech startup Ferronova secures A$11 million | https://www.biospectrumasia.com/news/98/21814/australian-biotech-startup-ferronova-secures-a11-m-to-advance-nanotech-image-guided-cancer-therapy.html
8. [Ferronova] Company website and news | https://www.ferronova.com.au/
9. [Fredrik Nyberg - MedTech Innovator, retrieved 2026] LinkedIn post on MedTech Innovator APAC Cohort | https://www.linkedin.com/in/nyberg/